化療肺癌患者使用中醫輔助療法（ImmuProp™）前後自覺健康狀況差異分析

Difference of Perceived Health Status among Lung Cancer Patients Underwent Chemotherapy and Chinese Supplement Medical Treatment (ImmuProp™)

研究背景：中西醫整合在臨床上能優勢互補，可減輕癌症患者化療產生副作用的不適感。瞭解肺癌病人使用中西醫治療健康狀況，可提供病患選用中西醫整合治療肺癌的參考。 研究目的：本研究主要目的為瞭解肺癌患者使用中醫輔助療法的自覺健康狀況差異，同時探討其副作用的差異。 研究方法：本研究為雙盲之實驗設計，實驗期間為2012年7月至2013年1月，隨機分配28位個案醫院化療肺癌患者到實驗組及控制組，實驗組在受試期間需每天服用ImmuProp™2次，控制組則給予外觀味道一致的安慰劑，受試者須在第1、3、5週回診填寫SF-36問卷及副作用問卷並進行例行性的抽血檢測。統計方法探卡方檢定、獨立樣本T檢定、配對樣本T檢定。 研究結果：在自覺健康狀況及副作用方面，實驗組及控制組兩組間均無顯著性差異，唯第3週的髮膚類有負向顯著差異（P=0.03），此外實驗組內的生理面向亦有負向顯著差異（在第3、5週，p=0.03）。 結論：實驗組內第3、5週生理面向及兩組間副作用在第3週髮膚類有負向的顯著差異，與實驗組及控制組的化療療程、劑量與兩組間的病程期別有關。本研究結果提供了肺癌病人中西醫治療的決策參考。 Background: Integration of Chinese and Western medicine in clinical practice can be complement each other dominantly, such as extenuating the side effects of chemotherapy among patients with lung cancer. Therefore, analyze the health status of lung cancer patients treated with combined treatment of western and traditional Chinese medicines is essential Objective: The objective of this study was to examine the health status and side effects among lung cancer patients treated with combined treatment of traditional Chinese medicine and chemotherapy. Method: This study was a double-blinded experimental design, randomly allocated 28 lung cancer patients treated with chemotherapy at the case hospital during July 2012 and January 2013 to experimental and control groups respectively. Subjects for experimental group were given ImmuProp™ (a supplement made of Chinese herbal medicine) twice a day; whereas, their counterparts received placebo. All the subjects were asked to complete the questionnaires of SF-36 and other information at one, three, and five weeks after they agree to participate in the study. In addition, routine blood samplings were conducted during the visits. Independent and paired t tests and chi-square test were adopted to analyze the differences between and within groups. Results: No significant differences were found between experimental and control groups, in terms of health status; however, significant adverse difference of hair loss was found (p=0.03). In addition, significant adverse difference of physical fonction within experimental group was found (week 3 vs. week 5, p=0.03). Conclusion: The significant adverse differences between and within groups on hair loss and physical function were probably due to the courses and dosage of chemotherapy among the subjects, which was highly related with the stage of cancer. The results of this study provided noteworthy information of treating lung cancer patients with modem and traditional Chinese medicines.